BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8235309)

  • 1. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
    Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
    Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
    Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
    Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer.
    Barton DP; Blanchard DK; Michelini-Norris B; Nicosia SV; Cavanagh D; Djeu JY
    Blood; 1993 Jan; 81(2):424-9. PubMed ID: 8422462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum soluble interleukin-2 receptor (sIL-2R) assay in cervical and endometrial cancer. Preliminary data.
    Ferdeghini M; Gadducci A; Prontera C; Marrai R; Malagnino G; Annicchiarico C; Fioretti P; Bianchi R
    Anticancer Res; 1993; 13(3):709-13. PubMed ID: 8317901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implication of serum sIL-2R levels in ovarian cancer.
    Wang S; Cai G; Lu Y
    J Tongji Med Univ; 1998; 18(2):126-8. PubMed ID: 10806842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
    Gebauer G; Rieger M; Jäger W; Lang N
    Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum soluble interleukin-2 receptor alpha levels in patients with gynecologic cancers: early effect of surgery.
    Barton DP; Blanchard DK; Michelini-Norris B; Roberts WS; Hoffman MS; Fiorica JV; Nicosia SV; Cavanagh D; Djeu JY
    Am J Reprod Immunol; 1993; 30(2-3):202-6. PubMed ID: 8311929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer.
    Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Gagetti O; Prontera C; Bianchi R; Facchini V
    Gynecol Oncol; 1995 Aug; 58(2):184-8. PubMed ID: 7542621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients.
    Pavlidis NA; Bairaktari E; Kalef-Ezra J; Nicolaides C; Seferiadis C; Fountzilas G
    Int J Biol Markers; 1995; 10(2):75-80. PubMed ID: 7561242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer.
    Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Annicchiarico C; Prato B; Bianchi R; Fioretti P
    Tumour Biol; 1992; 13(5-6):287-93. PubMed ID: 1290026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
    Elg SA; Hill RB; Heldman L; Ramakrishnan S
    Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
    Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
    Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?
    Buccheri G; Marino P; Preatoni A; Ferrigno D; Moroni GA
    Chest; 1991 Jun; 99(6):1433-7. PubMed ID: 2036827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
    Naumnik W; Chyczewska E
    Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
    Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Serum soluble interleukin-2 receptor levels in patients with renal cell carcinoma: a comparison of values before and after surgery].
    Tsukamoto S; Ishikawa S; Yamauchi A; Saitou S
    Hinyokika Kiyo; 2000 Oct; 46(10):695-9. PubMed ID: 11215193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
    Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
    Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
    Shaarawy M; Darwish NA; Abdel-Aziz O
    J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble interleukin-2 receptors (sIL-2R) in ovarian cancer patients: changes in sIL-2R after surgery as a prognostic factor?
    Gebauer G; Rieger M; Jäger W; Lang N
    Int J Biol Markers; 1998; 13(1):45-7. PubMed ID: 9681299
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.